MedTrace Logo

Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r

NCT00866021 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-03-17

No results posted yet for this study

Summary

The aim of this study is to assess the efficacy of lopinavir/r in monotherapy and peg-interferon plus ribavirin for the control of both HIV and HCV infection respectively after 12 months of active treatment for HCV.

Conditions

  • HIV/HCV Co-infection
  • HIV Infections

Interventions

DRUG

Lopinavir/ritonavir

NRTI sparing-regimen

DRUG

Lopinavir/ritonavir with two nucleoside analogs

LPV/r plus 2NRTIs + PEG-INF + RBV

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Fundacion SEIMC-GESIDA

    lead OTHER

Principal Investigators

  • Enrique Ortega · Hospital General Universitario de Valencia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-06-30
Completion
2012-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00866021 on ClinicalTrials.gov